CD36 receptor

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury

Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.